Annexon, Inc. (NASDAQ:ANNX) Shares Purchased by E Fund Management Co. Ltd.

E Fund Management Co. Ltd. grew its position in shares of Annexon, Inc. (NASDAQ:ANNX) by 36.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 15,447 shares of the company’s stock after acquiring an additional 4,086 shares during the quarter. E Fund Management Co. Ltd.’s holdings in Annexon were worth $79,000 as of its most recent filing with the SEC.

Several other institutional investors have also modified their holdings of the company. State Street Corp lifted its position in Annexon by 116.6% in the 3rd quarter. State Street Corp now owns 3,841,879 shares of the company’s stock valued at $22,744,000 after purchasing an additional 2,068,294 shares during the last quarter. Sio Capital Management LLC acquired a new stake in shares of Annexon in the third quarter valued at approximately $8,484,000. Charles Schwab Investment Management Inc. raised its holdings in shares of Annexon by 221.8% during the third quarter. Charles Schwab Investment Management Inc. now owns 732,216 shares of the company’s stock valued at $4,335,000 after buying an additional 504,656 shares during the last quarter. Mutual of America Capital Management LLC boosted its position in shares of Annexon by 56.2% during the fourth quarter. Mutual of America Capital Management LLC now owns 1,029,680 shares of the company’s stock worth $5,282,000 after buying an additional 370,426 shares during the period. Finally, Candriam S.C.A. grew its holdings in Annexon by 15.6% in the 4th quarter. Candriam S.C.A. now owns 2,534,230 shares of the company’s stock worth $13,001,000 after buying an additional 341,431 shares in the last quarter.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on the company. Needham & Company LLC reiterated a “buy” rating and set a $16.00 price target on shares of Annexon in a research report on Tuesday, March 4th. HC Wainwright reaffirmed a “buy” rating and issued a $30.00 price objective on shares of Annexon in a report on Tuesday, December 17th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Annexon in a research note on Friday, November 15th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $15.80.

Annexon Stock Up 3.0 %

Shares of ANNX stock opened at $2.76 on Monday. The stock has a 50-day simple moving average of $3.75 and a 200 day simple moving average of $5.33. Annexon, Inc. has a fifty-two week low of $2.30 and a fifty-two week high of $8.40. The stock has a market capitalization of $294.20 million, a P/E ratio of -2.63 and a beta of 1.14.

Annexon (NASDAQ:ANNX) last announced its quarterly earnings data on Monday, March 3rd. The company reported ($0.33) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.28) by ($0.05). On average, sell-side analysts anticipate that Annexon, Inc. will post -0.96 earnings per share for the current year.

About Annexon

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.